Natera,Inc. (NASDAQ:NTRA) Files An 8-K Other Events

ME Staff 8-k
-
0
Natera,Inc. (NASDAQ:NTRA) Files An 8-K Other Events

Natera,Inc. (NASDAQ:NTRA) Files An 8-K Other Events
Item 8.01. Other Events.

Natera,Inc. (“Natera” or the “Company”) has entered into a several million dollar agreement with a leading pharmaceutical company to participate in a prospective randomized clinical trial using a CLIA-validated Signatera™ custom circulating tumor DNA assay. The exploratory clinical outcomes study is expected to randomize early-stage cancer patients based on minimal residual disease measured by Signatera™ to receive a novel treatment versus standard of care therapy in the adjuvant setting. To the Company’s knowledge, this is the first such trial sponsored and managed by a pharmaceutical company. Based on data from the National Cancer Institute SEER Program, Natera estimates that there are over 1.8 million early-stage cancer patients in the U.S. alone.

Forward Looking Statements

This Current Report on Form8-K contains forward-looking statements, which statements are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. In addition, please note that the date of this Current Report on Form8-K is September12, 2018, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. We undertake no obligation to update these statements as a result of new information or future events.


About Natera,Inc. (NASDAQ:NTRA)

Natera, Inc. is a diagnostics company. The Company’s product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening (Horizon) to determine carrier status for various severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening (PGS) and Spectrum Pre-implantation Genetic Diagnosis (PGD) to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization (IVF) cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother’s blood and a blood sample from the alleged father(s).